Cargando…
The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation
BACKGROUND & AIMS: Despite recent advances in antiviral therapy for hepatitis C virus (HCV), a proportion of patients with genotype 3 (G3) HCV infection do not respond to current all oral treatment regimens. Genomic analyses have identified key polymorphisms correlating with increased resistance...
Autores principales: | Lee, Wing-Yiu Jason, Jones, Meleri, Wing, Peter A.C., Rajagopal, Swathi, Foster, Graham R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903130/ https://www.ncbi.nlm.nih.gov/pubmed/33248325 http://dx.doi.org/10.1016/j.jcmgh.2020.11.012 |
Ejemplares similares
-
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir
por: Wing, Peter A.C., et al.
Publicado: (2019) -
Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa
por: Wang, Shaoyang, et al.
Publicado: (2011) -
Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2010) -
The use of interferon-alfa in Behçet's disease: review of the literature
por: Kötter, I, et al.
Publicado: (2003) -
Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
por: Etoh, Reiko, et al.
Publicado: (2011)